Merck KGaA has updated sales expectations for its newly launched drugs in 2022, from around €2bn previously to €1.6-1.8bn, including moderating its sales ambitions for the multiple sclerosis drug Mavenclad, because of COVID-19-related effects.
However, peak sales forecasts for Mavenclad (cladribine) remain unchanged, at €1bn to €1.4bn, company CEO Belén Garijo told a briefing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?